122 related articles for article (PubMed ID: 10975384)
1. Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia.
Honma Y; Niitsu N
Leuk Lymphoma; 2000 Sep; 39(1-2):57-66. PubMed ID: 10975384
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic efficacy of 2-deoxycoformycin in monocytic leukemia cells.
Niitsu N; Yamamoto-Yamaguchi Y; Kasukabe T; Okabe-Kado J; Umeda M; Honma Y
Blood; 2000 Aug; 96(4):1512-6. PubMed ID: 10942399
[TBL] [Abstract][Full Text] [Related]
3. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3.
Niitsu N; Yamaguchi Y; Umeda M; Honma Y
Blood; 1998 Nov; 92(9):3368-75. PubMed ID: 9787175
[TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors.
Honma Y
Leuk Lymphoma; 2001; 42(5):953-62. PubMed ID: 11697650
[TBL] [Abstract][Full Text] [Related]
5. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
Niitsu N; Umeda M; Honma Y
Leuk Res; 2000 Jan; 24(1):1-9. PubMed ID: 10634639
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
8. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
9. Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine.
Niitsu N; Umeda M; Honma Y
Biochem Biophys Res Commun; 1997 Sep; 238(1):100-6. PubMed ID: 9299460
[TBL] [Abstract][Full Text] [Related]
10. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Cortes J; Kantarjian H; Talpaz M; O'Brien S; Beran M; Koller C; Keating M
Leukemia; 1997 Jun; 11(6):788-91. PubMed ID: 9177428
[TBL] [Abstract][Full Text] [Related]
12. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A).
Yu AL; Mendelsohn J; Matsumoto SS
Adv Exp Med Biol; 1986; 195 Pt A():491-6. PubMed ID: 3487920
[No Abstract] [Full Text] [Related]
13. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Pott-Hoeck C; Hiddemann W
Ann Oncol; 1995 May; 6(5):421-33. PubMed ID: 7669706
[TBL] [Abstract][Full Text] [Related]
14. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with purine nucleoside analogs.
Foss FM
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):31-5. PubMed ID: 10887642
[TBL] [Abstract][Full Text] [Related]
16. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Cheson BD; Vena DA; Barrett J; Freidlin B
J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
Cass CE; Au-Yeung TH
Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG
Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
[TBL] [Abstract][Full Text] [Related]
19. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
[TBL] [Abstract][Full Text] [Related]
20. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
